Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On June 28, 2022, the board of directors (the "Board") of Surface Oncology, Inc. (the "Company") appointed Carsten Brunn, Ph.D. as a member of the Company's Board and as a member of the Compensation Committee of the Board, effective as of June 28, 2022. Dr. Brunn will serve as a Class II director, to serve until the Company's annual meeting of stockholders in 2023 and until his successor is duly elected and qualified, or until his earlier resignation or removal.

Dr. Brunn has over 25 years of industry experience and since December 2018 has served as the President, Chief Executive Officer and member of the board of directors of Selecta Biosciences, Inc. ("Selecta"). Prior to joining Selecta, Dr. Brunn was the President of Pharmaceuticals for the Americas Region and a member of the Global Pharmaceutical Executive Committee at Bayer AG, a pharmaceutical company, since January 2017. Previously to that, he served as President of Bayer Pharmaceuticals in Japan, a role he held since March 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing pharmaceutical companies in Japan. Dr. Brunn has held a number of senior leadership positions at Eli Lilly, Novartis, Basilea and Bausch and Lomb in Europe, Asia and the United States. He currently serves on the board of directors of the Biotechnology Innovation Organization (BIO). Dr. Brunn holds a Ph.D. in Chemistry from the University of Hamburg and a Master of Science in Pharmaceutical Sciences from the University of Freiburg. He also studied at the University of Washington under a research scholarship and completed his executive education at London Business School. The Board believes Dr. Brunn's extensive experience as a senior executive of life sciences companies and knowledge of the pharmaceutical and biotechnology industries qualifies him to serve as a director of the Company.

Dr. Brunn will be compensated for his service as a non-employee director and will receive an initial option award to purchase 48,000 shares of the Company's common stock pursuant to the Company's 2018 Stock Option and Incentive Plan. As a non-employee director, Dr. Brunn is also entitled to receive an annual cash retainer of $40,000 as a member of the Board and an additional annual cash retainer of $5,000 as a member of the Compensation Committee of the Board.

The Company will enter into an indemnification agreement with Dr. Brunn in connection with his appointment to the Board, which is in substantially the same form as that entered into with the other directors of the Company. There are no other arrangements or understandings between Dr. Brunn and any other persons pursuant to which he was selected as a director, and Dr. Brunn has no family relationships with any of the executive officers or directors of the Company. Additionally, Dr. Brunn has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with the appointment of Dr. Brunn to the Company's Board, the Company issued a press release on June 29, 2022, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits

Exhibit
Number       Description

99.1           Press release issued by Surface Oncology, Inc. on June 29, 2022

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses